Edition:
United States

AEterna Zentaris Inc (AEZS.PH)

AEZS.PH on Philadelphia Stock Exchange

3.43USD
26 Sep 2016
Change (% chg)

-- (--)
Prev Close
$3.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,150
52-wk High
$15.42
52-wk Low
$2.64

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris reports Q2 loss per share $0.71
Tuesday, 9 Aug 2016 04:30pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports second quarter 2016 financial and operating results . Q2 loss per share $0.71 .Product development programs on track towards FDA submission in 2017.  Full Article

Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel
Monday, 1 Aug 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel . Company expects to complete phase 3 clinical trial in Q3 of 2016 . Company and Rafa have also entered into a supply agreement . Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex .Company will supply Zoptrex to Rafa for duration of license agreement.  Full Article

Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex
Friday, 1 Jul 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia . Co will be entitled to receive non-refundable upfront payment for license to Cyntec of co's intellectual property related to Zoptrex . Company expects to complete Phase 3 clinical trial in Q3 of 2016 for Zoptrex . Cyntec agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones .Company will receive royalties on future net sales of Zoptrex in Taiwan, 9 countries in Southeast Asia.  Full Article

Aeterna Zentaris says IND submission by Sinopharm A-Think
Tuesday, 14 Jun 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris announces IND submission by Sinopharm A-Think .Sinopharm A-Think pharmaceuticals co submitted IND for Zoptrex to Chinese state food and drug administration.  Full Article

Aeterna zentaris to file a NDA for zoptrex in first half of 2017
Monday, 6 Jun 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting . Phase III trial for endometrial cancer expected to be completed in Q3 2016 .To file a new drug application for zoptrex in first half of 2017.  Full Article

Aeterna Zentaris reports Q1 loss per share $0.37
Monday, 9 May 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports first quarter 2016 financial and operating results . Q1 loss per share $0.37 . Aeterna Zentaris Inc says expected average monthly operating burn rate of approximately $2.8 million during remainder of 2016 . Aeterna zentaris inc says Zoptrex(tm) (Zoptarelin Doxorubicin) pivotal phase 3 clinical program on track for completion in Q3 2016 .Says Zoptrex(Tm) Licensee in China and related territories, Sinopharm A-Think pharmaceuticals Co., Ltd., scheduled to file IND in Q2 2016.  Full Article

Aeterna Zentaris Inc announces leadership changes
Thursday, 18 Feb 2016 04:24pm EST 

Aeterna Zentaris Inc:Appoints geneviève lemaire as vice president, Finance and chief accounting officer.Keith Santorelli, the company's former vice president, Finance and chief accounting officer, has left the company.  Full Article

Aeterna Zentaris Announces Closing of US$16.65 Million Public Offering of Common Shares and Warrants
Monday, 14 Dec 2015 12:30pm EST 

Aeterna Zentaris Inc:closing of its previously announced underwritten public offering (of 3.0 million common shares and warrants to acquire 2.1 million common shares with a combined purchase price of US$5.55 for one common share together with a warrant to purchase 0.7 of a common share.generating net proceeds of approximately US$15.0 million.In addition, the Company granted the underwriter a 45-day option to purchase up to an additional 330,000 common shares and/or warrants to purchase up to an additional 231,000 common shares, to cover over-allotments, if any.Prior to closing, the underwriter exercised its over-allotment option with respect to the warrants to acquire an additional 231,000 common shares, resulting in an issuance of warrants to acquire an aggregate of 2,331,000 common shares at closing.Intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, for the potential addition of commercialized products to the Company's portfolio, and for general corporate purposes, for working capital and to fund negative cash flow.Maxim Group LLC acted as sole book-running manager, and H.C. Wainwright & Co., LLC acted as financial advisor to the Company in connection with the Offering.  Full Article

Aeterna Zentaris Inc announces pricing of $16.65 mln public offering of common shares and warrants
Wednesday, 9 Dec 2015 08:25am EST 

Aeterna Zentaris Inc:Announces pricing of US$16.65 million public offering of common shares and warrants.Underwritten public offering of common shares and warrants with a public offering price of US$5.55 for one common share.  Full Article

Aeterna Zentaris Inc announces proposed public offering of common shares
Tuesday, 8 Dec 2015 04:15pm EST 

Aeterna Zentaris Inc:Has commenced an underwritten public offering of common shares and warrants to purchase common shares.  Full Article